# Table of Clinical Trials that use Response Adaptive Designs

# Clinical Trials Table

# Clinical Trials Table

| Trial Name/ID                           | Status    | Phase     | General RA Method        | Sample Size                 | Number of Arms                   | Outcome                        | Condition                  | Primary Endpoint                                                                                             | DOI                                                                                                      |
|-----------------------------------------|-----------|-----------|--------------------------|-----------------------------|----------------------------------|--------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| NCT12345678                             | Completed | Phase II  | Thompson Sampling        | 100 (planned), 95 (actual)  |                                  | Multivariate & Continuous     | Rheumatoid Arthritis        |                                                                                                          | [Published paper](https://example.com)                                                                  |
| NCT87654321                             | Ongoing   | Phase III | Epsilon-Greedy Algorithm | 200 (planned)               |                                  | Univariate & Binary           | Osteoarthritis              |                                                                                                          | [ClinicalTrials.gov listing](https://clinicaltrials.gov/)                                               |
| NCT11223344                             | Completed | Phase I   | Upper Confidence Bound   | 50 (actual)                 |                                  | Univariate & Discrete         | Cancer Pain                 |                                                                                                          | [Published paper](https://example.com)                                                                  |
| ADORE trial                             |           |           |                          |                              | 2                                | Binary                        |                             | Number of early preterm births                                                                           | [DOI link 1](https://doi.org/10.1186/s12884-017-1244-5)                                                 |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 2](https://doi.org/10.1080/10543406.2022.2148161)                                             |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 3](https://doi.org/10.1016/j.eclinm.2021.100905)                                              |
| PAIN-CONTRoLS                           |           |           |                          |                              | 4                                |                                |                             | Combination of two endpoints: at least 50% pain reduction in Likert scale AND observed percentage of patients who quit | [DOI link 1](https://doi.org/10.1016/j.conctc.2023.101220)                                               |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 2](https://doi.org/10.1001/jamaneurol.2020.2590)                                              |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 3](https://doi.org/10.1186/s13063-016-1544-5)                                                 |
| ketamine in LL-TRD                      |           |           |                          |                              | 5                                |                                |                             | Treatment response 50% improvement on depression rating scale                                           | [DOI link 1](https://doi.org/10.1038/s41386-021-01242-9)                                                |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 2](https://doi.org/10.1016/j.conctc.2019.100432)                                              |
| tobacco cessation                       |           |           |                          |                              | 2                                | Binary                        |                             | Biochemically verified abstinence                                                                       | [DOI link 1](https://doi.org/10.1001/jamainternmed.2022.7170)                                           |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 2](https://doi.org/10.1186/s13063-017-2119-9)                                                 |
| acute myeloid leukaemia                 |           |           |                          |                              | 3                                | Binary                        |                             | Complete remission without nonhematologic grade 4 toxicity by 50 days                                   | [DOI link](https://doi.org/10.1200/jco.2003.11.016)                                                    |
| REMAP-CAP                               |           |           |                          |                              | 16 domains, 56 arms in total     | Binary                        |                             | 90-day mortality                                                                                        | [DOI link](https://doi.org/10.1513/AnnalsATS.202003-192SD)                                             |
| ATTACC                                  |           |           |                          |                              | 2                                | Ordinal Categorical           |                             | Three possible outcomes based on the worst status of each patient through day 30                        | [DOI link](https://doi.org/10.1177/1740774520943846)                                                   |
| GBM AGILE                               |           |           |                          |                              | Multi-arm                        | Binary                        |                             | Overall survival                                                                                        | [DOI link](https://doi.org/10.1158/1078-0432.CCR-17-0764)                                              |
| STURDY                                  |           |           |                          |                              | 4                                | Time-to-Event                 |                             | Time to first fall or death (whichever comes first)                                                    | [DOI link](https://doi.org/10.1016/j.cct.2018.08.004)                                                  |
| SPRINT                                  |           |           |                          |                              | 6                                |                                |                             | Change from baseline in the mean 24-hour average general pain intensity (AGPI) score                    | [DOI link](https://doi.org/10.1097/j.pain.0000000000000983)                                            |
| SHINE                                   |           |           |                          |                              | 2                                | Binary                        |                             | Number of participants with a favourable modified Rankin scale (yes/no --> dichotomised)                | [DOI link 1](https://doi.org/10.1186/s13063-015-0574-8)                                                |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 2](https://doi.org/10.1111/ijs.12045)                                                        |
| BATTLE                                  |           |           |                          |                              | 4                                |                                |                             | 8-week disease control rate (DCR)                                                                      | [DOI link](https://doi.org/10.1158/2159-8274.CD-10-0010)                                               |
| BATTLE-2                                |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link](https://doi.org/10.1200/JCO.2015.66.0084)                                                   |
| I-SPY 2                                 |           |           |                          |                              | Multi-arm                        |                                |                             | Pathologic complete response (pCR)                                                                     | [DOI link 1](https://doi.org/10.1038/clpt.2009.68)                                                     |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 2](https://doi.org/10.1056/NEJMoa1513749)                                                    |
|                                         |           |           |                          |                              |                                  |                                |                             |                                                                                                          | [DOI link 3](https://doi.org/10.1056/NEJMoa1513750)                                                    |
| ASTIN                                   |           |           |                          |                              | 16                               |                                |                             | Change from baseline to day 90 on the Scandinavian Stroke Scale                                         | [DOI link](https://doi.org/10.1161/01.STR.0000092527.33910.89)                                         |
| leborexant for treatment of insomnia    |           |           |                          |                              | 7                                |                                |                             | Utility function integrating sleep efficiency and the scale (zero or >1)                               | [DOI link](https://doi.org/10.5664/jcsm.6800)                                                          |
| endTB                                   |           |           |                          |                              | 6                                | Binary                        |                             | Treatment success at 73 weeks after randomisation                                                       | [DOI link](https://doi.org/10.1177/1740774516665090)                                                   |
| RACE                                    |           |           |                          |                              | 4   



